Literature DB >> 6788045

[Factor VIII concentrate, highly purified and heated in solution (author's transl)].

N Heimburger, H Schwinn, P Gratz, G Lüben, G Kumpe, B Herchenhan.   

Abstract

A process is described to produce a highly purified factor VIII concentrate heated in solution. Pooled cryoprecipitate from citrated plasma is adsorbed on aluminum hydroxide gel. The fibrinogen is removed by heat denaturation in the presence of glycine; factor VIII is precipitated with sodium chloride from the supernatant. The precipitate is dissolved in a saccharose/glycine solution and heated at 60 degrees C for 10 h. The factor VIII is then separated by further precipitation with sodium chloride, the precipitate dissolved, dialysed and sterilized by filtration. The factor VIII concentrate contains approximately 6 units F VIII:C per mg protein. the ratio of F VIII R:Ag/F VIII:C is 3. The product is free from coagulable protein and gamma-globulins. The efficacy of the heating step in the reduction of the hepatitis B-infectious titre was proved in chimpanzees. For this purpose, hepatitis B virus was added to the pooled cryoprecipitate.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6788045

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

Review 2.  Transmission of diseases by blood transfusion.

Authors:  S Seidl; P Kühnl
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

3.  [Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate].

Authors:  N Heimburger
Journal:  Blut       Date:  1982-04

4.  Hepatitis safety of a new prothrombin complex preparation, sterilized according to the method of LoGrippo. Results of a prospective clinical trial.

Authors:  I Hoppe
Journal:  Blut       Date:  1985-06

Review 5.  The development of virus-free labile blood derivatives--a review.

Authors:  A M Prince; B Horowitz; M S Horowitz; E Zang
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.